Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Thrive Care: Internet CBT for Depression

7. mars 2018 oppdatert av: Kaiser Permanente

The Thrive Care Study: Computer-Delivered Cognitive Behavioral Therapy as Care Augmentation for Depressed Primary Care Patients

This project will study the effectiveness of computerized cognitive behavioral therapy (CBT) in reducing depression symptoms. The design is a two-arm randomized controlled trial comparing (i) control arm, which is treatment as usual with (ii) treatment arm, which is treatment as usual plus computerized CBT. The primary outcome measure is change in depression symptom severity. The name of the computerized CBT program to be used in the study is Thrive.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Population:

  • As identified in Epic, Kaiser Permanente Southern California (KPSC) Fontana Family Medicine patients with a depression diagnosis recorded during the prior week (rolling basis).
  • Target study enrollment: 150 participants per arm (300 total)

Recruitment:

  • Kaiser Permanente (KP) will send eligible patients a postal letter inviting them to participate in study. Interested patients will be directed to the Enrollment/Assessment Website, a website to be developed by vendor Waypoint Health Innovations. The recruitment letter will contain (i) a description of the study, (ii) the web address for the Enrollment/Assessment Website, (iii) the patient's Study Identifier (ID).
  • Additionally, KP will send eligible patients for whom KP has an email address an email inviting them to participate in the study.

Screening and Enrollment (Enrollment/Assessment Website):

  • A patient interested in applying to the study will visit the Enrollment/Assessment Website and input his/her unique Study ID. The website will verify that the entered Study ID is on a pre-loaded list. If valid, the patient may continue to screening assessments.
  • Patient will complete the 9-item Patient Health Questionnaire (PHQ-9) depression symptom assessment. Patients with eligible PHQ-9 scores may continue to Informed Consent page.
  • The Informed Consent (IC) page will contain (i) the Informed Consent text including contact information for any questions patient may have; (ii) fields for first name, last name, date of birth, email address, and phone number; (iii) a check box labeled "I understand the above information and agree to participate…" (or similar); and (iv) a "submit" (or similar) button.
  • To enroll in the study, the patient must complete all fields, check the box, and click submit button. The website will validate that every field has been completed and that the phone number and email fields have the correct format (e.g. name@domain.com for the email field).
  • If all fields are complete, the website will store the Study ID, first name, last name, date of birth, email address, and phone number that patient entered into the website. They will be stored in an encrypted database for use by researchers.
  • Additionally, the website will store the complete Informed Consent page (including Informed Consent text, first name, last name, date of birth, email address, phone number, and checked box) in a single encrypted record, timestamp it, and place a digital certificate on it. The digital certificate will allow us to prove that no one tampered with any part of the IC document after the participant clicked submit.
  • The website automatically randomizes participants to treatment or control arm. Participants continue in website to baseline assessments.
  • After baseline assessments, control arm participants go to a page in the Enrollment/Assessment Website telling them to expect assessment again in 2 months, while treatment arm participants will be given instructions for enrolling in Thrive.
  • Researchers would have access to the completed IC forms to print and/or mail to patients who request a copy.
  • Weekly, KP research coordinator will review new participants' study ID, name, and date of birth (DOB) the participant entered to ensure they match KP records. Individuals who entered information that does not reasonably match KP records would be removed from the study.

Coaching:

• KP will send each treatment arm participant four emails encouraging them to use Thrive, with the exception that the second email will be replaced by a phone call from KP for patients who have not achieved a minimum level of activity in Thrive at that point.

Endpoint and Follow-up Assessments:

• KP will ask each study participant to visit Enrollment/Assessment Website 2 and 6 months after study enrollment to complete assessments.

Studietype

Intervensjonell

Registrering (Faktiske)

304

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Fontana, California, Forente stater, 92335
        • Kaiser Fontana Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Per EPIC (or other system) records, clinical depression was addressed during the prior week by a KPSC Fontana Family Medicine physician , reflected by an ICD-9 or ICD-10 diagnosis of Depression, Major Depressive Disorder, Dysthymia, Adjustment Disorder with Depressed Mood, and Depression Not Otherwise Specified. This does not have to be the patient's first depression diagnosis.
  • Screening Patient Health Questionnaire (PHQ-9) score of ≥5 as measured in Assessment Website (see Section 4 for information on Assessment Website)

Exclusion Criteria:

  • History or current diagnosis indicating any Schizophrenia spectrum or other psychotic disorder, any Neurocognitive disorder, Delirium, Bipolar disorder, Intellectual disability, or Personality disorder, or any active substance abuse, as defined by DSM-5
  • Member is not proficient in English
  • Member answered "more than half the days" or "nearly every day" on the Patient Health Questionnaire ninth item and did not subsequently answer (regarding suicidal ideations) "Yes" to the question "are you sure you can stay safe?"

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Control Arm
After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
Eksperimentell: Intervention Arm
After enrollment in the study, the subject will be granted 8 weeks of access to "Thrive", an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
Andre navn:
  • Thrive for Depression

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PHQ-9 score change
Tidsramme: 0-6 months after enrollment
Change in score on the 9-item Patient Health Questionnaire
0-6 months after enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
GAD-7 score change
Tidsramme: 0-6 months after enrollment
Change in score on 7-item Generalized Anxiety Disorder scale
0-6 months after enrollment
Quality of Life change
Tidsramme: 0-6 months after enrollment
Change in subjective measure of subject's quality of life (based on Behavioral Risk Factor Surveillance System)
0-6 months after enrollment
Workplace productivity change
Tidsramme: 0-6 months after enrollment
Change in subjective measure of subject's workplace productivity (based on Behavioral Risk Factor Surveillance System)
0-6 months after enrollment
Medication adherence
Tidsramme: 0-6 months after enrollment
Measure of compliance with prescribed medications, based on a single item question
0-6 months after enrollment
Psychotherapy utilization
Tidsramme: 12 months prior to enrollment, through 6 months after enrollment
Subjective measurement of whether or not the subject has received psychotherapy from a licensed provider
12 months prior to enrollment, through 6 months after enrollment
Psychiatric specialty utilization
Tidsramme: 0-6 months after enrollment
Subjective measurement of whether or not the subject has received treatment from a provider in the Department of Psychiatry
0-6 months after enrollment
Satisfaction with Thrive
Tidsramme: 2 months after enrollment
Subjective measurement of how satisfied patient was with the treatment intervention
2 months after enrollment
Satisfaction with Kaiser Permanente Southern California
Tidsramme: 0-6 months after enrollment
Subjective measurement of how satisfied patient was with their experience of care at Kaiser Permanente Southern California
0-6 months after enrollment
Thrive Adherence
Tidsramme: 0-2 months after enrollment
Percent enrolled in Thrive over total number invited, number of logins and lessons started
0-2 months after enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Roderick R Stuart, MD, Southern California Permanente Medical Group

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. april 2017

Primær fullføring (Faktiske)

13. desember 2017

Studiet fullført (Faktiske)

13. desember 2017

Datoer for studieregistrering

Først innsendt

1. februar 2017

Først innsendt som oppfylte QC-kriteriene

8. mars 2017

Først lagt ut (Faktiske)

15. mars 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. mars 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. mars 2018

Sist bekreftet

1. mars 2018

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

3
Abonnere